CA
NZ
UK
AU
IND
US
Travel nurses working under 1099 contracts often overlook powerful retirement savings tools designed for independent workers. Without a Solo 401(k), these professionals may forfeit the chance to reduce taxable income while building a nest egg. The structure of 1099 work creates unique financial planning …
Travere Therapeutics has outlined a succession plan within its finance organization, designating John Torell as the forthcoming chief accounting officer. This move follows the announced retirement of Sandra Calvin, who presently holds the chief accounting officer role.
Traws Pharma (NASDAQ: TRAW) secured shareholder approval to expand its 2021 Incentive Compensation Plan by 2,000,000 shares. The amendment, which took effect following the vote, increases the pool of common stock available for equity-based awards to employees and executives. This adjustment aligns with the …
Iovance Biotherapeutics’ strong quarterly results are energizing the broader biotech environment, prompting investors to reconsider exposure to firms advancing personalized cell‑based therapies. The combination of share price appreciation and revenue acceleration underscores market enthusiasm for novel melanoma approaches and may bolster interest in companies …
Medline Inc. (NASDAQ: MDLN) reported a senior leadership change on July 9, 2026. The company said its Chief Operating Officer, Stephen L. Miller, will step down due to health reasons, with the exit slated for August 30, 2026.
Medline Inc. (NASDAQ: MDLN) reported a senior leadership change on July 9, 2026. The company said its Chief Operating Officer, Stephen L. Miller, will step down due to health reasons, with the exit slated for August 30, 2026.
NEXGEL, INC. Has announced a delay for its 2026 Annual Meeting of Stockholders, shifting the date from July 10 to July 31, 2026. This decision aims to provide the company with additional time to gather necessary proxies for an array of proposals scheduled for …
Nurix Therapeutics, Inc. (NASDAQ: NRIX) has announced its quarterly financial results, providing insight into the company's performance. The results are a key indicator of the company's progress in the healthcare sector. The announcement was made on July 9, 2026.
These warrants, originally issued with an exercise price of $2.60 and set to expire in 2025, were adjusted to a lower price of $1.35 per share. As part of this transaction, the company issued additional warrants for up to 6,601,632 shares of its common …
Ionis Pharmaceuticals (NASDAQ: IONS) announced its experimental drug eplontersen failed to achieve the primary goal in a late-stage study for transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). The CARDIO-TTRansform Phase 3 trial did not demonstrate a statistically significant benefit in reducing cardiovascular mortality or recurrent clinical events …
Please wait processing your request...